SPDR S&P Biotech ETF
472 hedge funds and large institutions have $6.29B invested in SPDR S&P Biotech ETF in 2019 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 122 increasing their positions, 157 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
472
Holders Change
+66
Holders Change %
+16.26%
% of All Funds
9.32%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.22%
New
108
Increased
122
Reduced
157
Closed
35
Calls
$882M
Puts
$3.12B
Net Calls
-$2.24B
Net Calls Change
-$1.26B
Top Buyers
| 1 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$454M |
| 2 |
Goldman Sachs
New York
|
+$367M |
| 3 |
N
Natixis
Paris,
France
|
+$187M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$122M |
| 5 |
Barclays
London,
United Kingdom
|
+$78.9M |
Top Sellers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$1,000M |
| 2 |
JPMorgan Chase & Co
New York
|
-$620M |
| 3 |
Citigroup
New York
|
-$185M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$69.9M |
| 5 |
DA
Duality Advisers
Miami,
Florida
|
-$67.2M |
